Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications, where the company can partially or completely participate in the commercialization.
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon, which has successfully completed a Phase 2b clinical trial, as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure.
Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Calliditas aims to take Nefecon through a global Phase 3 study to commercialization. In addition, the company has identified other potential uses of Nefecon in niche indications and will investigate the development of these to provide new medications for patients with unmet medical needs.
The company was founded in 2004 under the name Pharmalink AB and is based in Stockholm, Sweden.